Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.

Wu B, Melhem M, Subramanian R, Chen P, Jaramilla Sloey B, Fouqueray B, Hock MB, Skiles GL, Chow AT, Lee E.

J Clin Pharmacol. 2018 Jun;58(6):717-726. doi: 10.1002/jcph.1090. Epub 2018 Mar 13. Review.

PMID:
29534286
2.

Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.

Subramanian R, Zhu X, Hock MB, Sloey BJ, Wu B, Wilson SF, Egbuna O, Slatter JG, Xiao J, Skiles GL.

Clin Pharmacokinet. 2017 Feb;56(2):179-192. doi: 10.1007/s40262-016-0433-0.

3.

Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.

Edson KZ, Wu BM, Iyer A, Goodman W, Skiles GL, Subramanian R.

Kidney Int Rep. 2016 Apr 21;1(1):24-33. doi: 10.1016/j.ekir.2016.04.002. eCollection 2016 May.

4.

Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).

Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, Walter S, Fitzsimmons M, Wagner M, Soto M, Pham R, Wilson SF, Skiles GL.

Drug Metab Dispos. 2016 Aug;44(8):1319-31. doi: 10.1124/dmd.115.068007. Epub 2016 Feb 19.

PMID:
26895981
5.

P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors.

Subramanian R, Aidasani D, Bailey K, Branstetter D, Everds N, Jiang J, Norman MH, Primack R, Skiles GL, Soto I, Stec MM, Wagner M, Wu T, Zhu X, Lebrec H.

Toxicol Sci. 2014 Nov;142(1):298-310. doi: 10.1093/toxsci/kfu178. Epub 2014 Aug 26.

PMID:
25159132
6.

Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.

Zhu X, Slatter JG, Emery MG, Deane MR, Akrami A, Zhang X, Hickman D, Skiles GL, Subramanian R.

Xenobiotica. 2013 Jul;43(7):617-27. doi: 10.3109/00498254.2012.747711. Epub 2012 Dec 17.

PMID:
23244593
7.

A novel biotransformation of alkyl aminopyrrolidine to aminopiperidine ring by human CYP3A.

Chen Y, Skiles GL, Shou M, Hickman D, Hsieh F.

Drug Metab Dispos. 2011 Sep;39(9):1668-73. doi: 10.1124/dmd.111.039750. Epub 2011 Jun 14.

PMID:
21673127
8.

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.

Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL.

Drug Metab Dispos. 2011 Jul;39(7):1139-48. doi: 10.1124/dmd.111.038067. Epub 2011 Mar 25.

PMID:
21441468
9.

Novel cytochrome p450 bioactivation of a terminal phenyl acetylene group: formation of a one-carbon loss benzaldehyde and other oxidative products in the presence of N-acetyl cysteine or glutathione.

Subramanian R, Tam J, Aidasani D, Reid DL, Skiles GL.

Chem Res Toxicol. 2011 May 16;24(5):677-86. doi: 10.1021/tx1004375. Epub 2011 Mar 11.

PMID:
21395287
10.

Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening.

Subramanian R, Lee MR, Allen JG, Bourbeau MP, Fotsch C, Hong FT, Tadesse S, Yao G, Yuan CC, Surapaneni S, Skiles GL, Wang X, Wohlhieter GE, Zeng Q, Zhou Y, Zhu X, Li C.

Chem Res Toxicol. 2010 Mar 15;23(3):653-63. doi: 10.1021/tx900414g.

PMID:
20095585
11.

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.

Xu L, Chen Y, Pan Y, Skiles GL, Shou M.

Drug Metab Dispos. 2009 Dec;37(12):2330-9. doi: 10.1124/dmd.108.025494. Epub 2009 Sep 22.

PMID:
19773538
12.

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.

Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, Skiles GL.

Drug Metab Dispos. 2008 Nov;36(11):2355-70. doi: 10.1124/dmd.108.020602. Epub 2008 Jul 31.

PMID:
18669588
14.

Biosynthesis of drug metabolites using microbes in hollow fiber cartridge reactors: case study of diclofenac metabolism by Actinoplanes species.

Osorio-Lozada A, Surapaneni S, Skiles GL, Subramanian R.

Drug Metab Dispos. 2008 Feb;36(2):234-40. Epub 2007 Nov 15.

PMID:
18006646
15.

Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.

Zhang D, Raghavan N, Chen SY, Zhang H, Quan M, Lecureux L, Patrone LM, Lam PY, Bonacorsi SJ, Knabb RM, Skiles GL, He K.

Drug Metab Dispos. 2008 Feb;36(2):303-15. Epub 2007 Nov 5.

PMID:
17984286
16.

Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity.

Mortishire-Smith RJ, Skiles GL, Lawrence JW, Spence S, Nicholls AW, Johnson BA, Nicholson JK.

Chem Res Toxicol. 2004 Feb;17(2):165-73.

PMID:
14967004
17.

Detection and characterization of DNA adducts of 3-methylindole.

Regal KA, Laws GM, Yuan C, Yost GS, Skiles GL.

Chem Res Toxicol. 2001 Aug;14(8):1014-24.

PMID:
11511175
18.
19.

Evidence supporting the formation of 2,3-epoxy-3-methylindoline: a reactive intermediate of the pneumotoxin 3-methylindole.

Skordos KW, Skiles GL, Laycock JD, Lanza DL, Yost GS.

Chem Res Toxicol. 1998 Jul;11(7):741-9.

PMID:
9671536
20.

Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity.

Amore BM, Kalhorn TF, Skiles GL, Hunter AP, Bennett GD, Finnell RH, Nelson SD, Slattery JT.

Drug Metab Dispos. 1997 Aug;25(8):953-62.

PMID:
9280403
21.

Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).

Prahalada S, Tarantal AF, Harris GS, Ellsworth KP, Clarke AP, Skiles GL, MacKenzie KI, Kruk LF, Ablin DS, Cukierski MA, Peter CP, vanZwieten MJ, Hendrickx AG.

Teratology. 1997 Feb;55(2):119-31.

PMID:
9143092
22.

Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse.

Bennett GD, Amore BM, Finnell RH, Wlodarczyk B, Kalhorn TF, Skiles GL, Nelson SD, Slattery JT.

J Pharmacol Exp Ther. 1996 Dec;279(3):1237-42.

PMID:
8968346
23.

Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole.

Skiles GL, Yost GS.

Chem Res Toxicol. 1996 Jan-Feb;9(1):291-7.

PMID:
8924606
24.

Metabolism and bioactivation of 3-methylindole by Clara cells, alveolar macrophages, and subcellular fractions from rabbit lungs.

Thornton-Manning JR, Nichols WK, Manning BW, Skiles GL, Yost GS.

Toxicol Appl Pharmacol. 1993 Oct;122(2):182-90.

PMID:
8212000
25.

Identification of goat and mouse urinary metabolites of the pneumotoxin, 3-methylindole.

Smith DJ, Skiles GL, Appleton ML, Carlson JR, Yost GS.

Xenobiotica. 1993 Sep;23(9):1025-44.

PMID:
8291262
26.

Identification of a cysteinyl adduct of oxidized 3-methylindole from goat lung and human liver microsomal proteins.

Ruangyuttikarn W, Skiles GL, Yost GS.

Chem Res Toxicol. 1992 Sep-Oct;5(5):713-9.

PMID:
1446013
27.

Isolation of a mercapturate adduct produced subsequent to glutathione conjugation of bioactivated 3-methylindole.

Skiles GL, Smith DJ, Appleton ML, Carlson JR, Yost GS.

Toxicol Appl Pharmacol. 1991 May;108(3):531-7.

PMID:
2020974
28.

Toxicity of 3-methyleneoxindole, a proposed reactive intermediate in the metabolism of 3-methylindole.

Appleton ML, Larson DN, Skiles GL, Nichols WK, Yost GS.

Adv Exp Med Biol. 1991;283:245-8. No abstract available.

PMID:
2068989
29.

Isolation and identification of 3-hydroxy-3-methyloxindole, the major murine metabolite of 3-methylindole.

Skiles GL, Adams JD Jr, Yost GS.

Chem Res Toxicol. 1989 Jul-Aug;2(4):254-9.

PMID:
2519781

Supplemental Content

Loading ...
Support Center